Institute news

John Brumby retires as ONJCRI’s inaugural Chair - Jenny Macklin to become new Chair

Published 16 October 2019


NHMRC grants focus on new cancer therapies research

Published 1 October 2019

180315 ONJCRI MR 0077

Community support boosts research technology

Published 4 June 2019



Repurposing existing drugs to treat gastric cancers

Published 15 May 2019




Love Your Sister and ONJCRI partnership focuses on the future of personalised medicine

Published 12 March 2019

LYS and ONJCRI partnership



Scanning barcodes to beat breast cancer

Published 12 March 2019

Dr Delphine Merino stands in the ONJCWRC garden

ACRF Award $2 Million To ONJCRI

Published 9 November 2018

P1050575ACRF logo team web












Ian Potter Foundation - Support of the ONJCRI

Published 8 November 2018


Dr Andreas Behren, Head of the Tumour Immunology Laboratory




After five years as the inaugural Chair of the Olivia Newton-John Cancer Research Institute (ONJCRI), The Hon John Brumby has announced that he will step down from the role, effective 1 November 2019.

Mr Brumby was instrumental in guiding the direction of the ONJCRI when it commenced in 2015 and has been a strong advocate and representative since this time.  Under his leadership, the research team has grown significantly and the outcomes from these projects are having life-changing impact for people with cancer.  His passion has consistently helped to motivate and drive the work of the ONJCRI team and we acknowledge the impact his leadership has had on the Institute’s success to date, including the more than 230 research collaborations and 140 scientific papers published over the last year.

ONJCRI is thrilled to announce that Ms Jenny Macklin has joined the ONJCRI Board and will take over the role of Chair from 1 November 2019.

Read more




We are delighted to confirm that two Olivia Newton-John Cancer Research Institute (ONJCRI) researchers have been awarded over $4.5 million in funding for the next 5 years in the inaugural round of the National Health and Medical Research Council’s (NHMRC) Investigator Grant scheme, announced by Federal Health Minister Greg Hunt.

This significant investment will allow the ONJCRI, as the La Trobe School of Cancer Medicine, to continue research into the use of imaging techniques for targeted treatments, and the development of novel anti-cancer therapies. 

“As an Institute, we are committed to conducting research that we believe can have the greatest impact on the availability of new cancer treatments, and in turn improve outcomes for people impacted by cancer,” said Prof Ernst, Scientific Director, ONJCRI.

Read more


For researchers at the Olivia Newton-John Cancer Research Institute (ONJCRI), it is critical that they have access to the latest cutting-edge equipment in order to undertake their groundbreaking research.

Without certain pieces of technology, it can be difficult for them to carry out their work with the specific attention to detail that cancer research demands. This equipment is often very expensive however, so generous donations to the ONJCRI are therefore crucial in order to acquire this technology.

Three women who work at Scotch College recently set up a fundraising event in memory of loved ones lost to cancer. They raised $37,000 at their Girls Night Out event, all of which was donated to the ONJCRI. Now, the funds have been used to buy a cryostat; a vital piece of equipment for researchers in the Translational Breast Cancer Program.

Dr Normand Pouliot, head of the Matrix Microenvironment and Metastasis Laboratory, is working to identify biomarkers (such as particular proteins, DNA and RNA) that could help clinicians predict which patients are likely to see their disease recur or who could benefit from certain treatments. Being able to utilise the cryostat has provided a massive boost to his research, and has also transformed the work of many of his ONJCRI colleagues.

Read more


Over 17,000 Australians are diagnosed with gastrointestinal cancers every year and 80 die from the disease each week.

With such hard hitting statistics, there is a very real urgency to develop new treatments for one of the nation’s most common cancers. Unfortunately, it often takes years for drugs to be made available after being discovered in the laboratory and the sad reality is that many patients can’t afford to wait this long.

Dr Ashwini Chand of the Olivia Newton-John Cancer Research Institute has published a paper this month through the European Molecular Biology Organisation (EMBO) that investigates a novel way of bypassing this lengthy development process. Her team in the Cancer Therapeutics Development Group is working to repurpose drugs already being used to treat other diseases for cancer therapy. Because these drugs have already passed clinical trial stage, they can hopefully be prescribed to cancer patients sooner.

“The concept of repurposing how an existing drug is used favours identifying drugs with greater tolerability in patients,” explains Ashwini. “An additional possible benefit for cancer patients and their families is that off-patent drugs are more easily accessible as treatments and are not as costly.”

Read more


While we often hear in the media that the survival rate of women diagnosed with breast cancer is increasing, unfortunately the survival rate for women with secondary breast cancer – also known as metastatic breast cancer - paints a very different picture.

Love Your Sister and the Olivia Newton-John Cancer Research Institute (ONJCRI) are now working together to try and change this statistic with the help of a dedicated Research Assistant who will work with ONJCRI researchers Dr Belinda Yeo  and Dr Delphine Merino  - two of Australia’s leading breast cancer research experts.

Belinda is a medical oncologist who treats breast cancer patients.  Delphine runs a breast cancer lab at ONJCRI that specifically deals with the cancer cells responsible for forming metastatic cancers. And while they make a great team, this new Research Assistant will bridge a gap to turn their ultimate goal of giving women with metastatic breast cancer alternative treatment options.

The initial 3 years study which will be conducted onsite at ONJCRI will see the Research Assistant obtain necessary consent from patients who are willing to donate their tumour sample to research, transport the precious samples to the laboratory and process it through the ONJCRI Tumour Progression and Heterogeneity Laboratory part of the  ONJCRI Translational Breast Cancer Program led by renowned breast cancer researcher Professor Robin Anderson

Read more

Dr Delphine Merino and her team are using a technique commonly found in the aisles of supermarkets to conduct cutting-edge cancer research.

Their work follows on from a paper Delphine co-authored which was published in the prestigious journal Nature Communications.

Her team at the Institute is using barcodes to identify, track and analyse the genetic properties of aggressive breast cancer cells that spread to other parts of the body or resist drug treatment.

Delphine co-authored a paper in the journal Nature Communications, which she produced with Dr Salin Naik, Professor Jane Visvader and Professor Geoffrey Lindeman at the Walter and Eliza Hall Institute of Medical Research.

Their study shows that the barcoding technique can be used to track how breast cancer cells spread to different parts of the body.

The researchers found that only a few cells were responsible for the metastasis of a tumour and these cells were the ‘seeds’ causing new tumour growth.

The research is an important step in understanding how cancer cells spread from the breast to other organs.

Read more

ACRF Centre for Imaging the Tumour Environment is a state of the art imaging centre to understand how and why tumours corrupt the normal cells of their immediate environment.

The Australian Cancer Research Foundation awarded the Olivia Newton John Cancer Research Institute $2million to establish this centre.  The centre enables ONJCRI and La Trobe Institute of Molecular Science to extend its ground- breaking work and accelerate the transition of laboratory results into cancer treatments that will benefit all Australian Cancer patients. 

“This new centre will allow us to look at the environment in which cancer cells and tumours grow, giving us the information we need to develop effective, targeted antic-cancer therapies”  

Prof Matthias Ernst, Scientific Director of ONJCRI & Head of the School of Cancer Medicine Latrobe University

To find out more about the Australian Cancer Research Foundation, please visit www.acrf.com.au

In 2015 The Ian Potter Foundation awarded a grant of $450,000 to the Olivia Newton-John Cancer Research Institute to partially fund the purchase of a Vectra System.

This equipment allows researchers to visualise multiple cell types in a single tumour and therefore characterise normal and abnormal cells within a samples.  It has allowed us to comprehensively analyse a patient's cancer and immune make-up to identify biomarkers of treatment response. This informs the selection of patients for clinical trials with immune therapeutics. This equipment has quickly become a highly sought after resource by our research teams and collaborators, which prompted a submission to the Ian Potter Foundation in support of the automation equipment to improve the sample processing time and allow a higher throughout put of use by researchers.

The purchase of the Vectra system in 2015 was also supported with funding from ONJCRI, La Trobe University, the Peter MacCallum Cancer Centre and Austin Health.

In September 2018 the ONJCRI, with co-funding support from La Trobe University, and support of the Victorian Comprehensive Cancer Centre - VCCC and the Peter MacCallum Cancer Centre, was awarded a further grant to support the purchase of the automation equipment. 

Along with these supporting research institutes, the equipment will support all member institutes of the Victorian VCCC including the PDI, Austin health and Walter and Eliza Hall Institute.  The addition of this vital equipment to the ONJCRI is an illustration of the collaborative work of researchers from Melbourne cancer research teams.

The grants, each lead by Dr Andreas Behren, Head of the Tumour Immunology Laboratory, together provide a platform of technology that is at the forefront of cancer patient sample analysis.  As a member of the VCCC, this equipment will enhance the VCCCs capacity to perform world‐class medical research and further strengthen and enhance cross‐institutional collaboration including academic‐industry and hospital‐academic cross‐collaborations.

The ONJCRI welcomes researchers wishing to use the equipment in their research. To find out more please contact Dr Andreas Behren: andreas.behren@onjcri.org.au